SEC Form 4 · accession 0001209191-18-033787
SURMODICS INC · SRDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles W Olson
Officer — Senior VP of Bus Dev, Med Dev
Period of report
May 24, 2018
Accepted (ET)
May 29, 2018 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000924717
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 24, 2018 | S | 18,760 | $48.4827 | D | 33,467 | D | |
| Common StockF3 | May 24, 2018 | S | 1,240 | $49.3923 | D | 32,227 | D | |
| Common Stock | holding | — | — | — | 800 | I | By IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018.
- F2Reflects the weighted average price of 18,760 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on May 24, 2018 with sale prices ranging from $48.25 to $49.15 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Reflects the weighted average price of 1,240 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on May 24, 2018 with sale prices ranging from $49.30 to $49.425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.